You are here
The content on this page and other TGA archive pages is provided to assist research and may contain references to activities or policies that have no current application. See the full archive disclaimer.
Testing of biological medicines
Applicable to biological medicines, excluding vaccines, anti-venoms and toxins
Evaluations and initial risk groups
During the evaluation process, we assign your biological medicine to a risk group using the risk assessment tool.
Your application to register a new biological medicine is:
- managed through the prescription medicines registration process
- submitted using the electronic submission process
- assigned a risk group during the course of evaluation
Variations to prescription medicines - excluding variations requiring evaluation of clinical or bioequivalence data: Process guidance outlines the normal Category 3 and self-assessable notification processes.
Impact of significant manufacturing changes on the assigned risk group
If you have a significant change in a manufacturing process, you are required to complete a comparability study before and after the change.
We will review the assigned risk group and notify you if any change is required, such as to:
- the assigned risk group, which may increase if the risk level is increased
- your release procedures, if the new risk group requires batch or protocol release
Changes to test methods or specifications
Requirements for batch or protocol release
We assess the requirements for batch or protocol release testing during the evaluation process. The Delegate considers all recommendations and their suitability for inclusion in the approval letter.
Additional information which may be requested
If test methods used in the analysis of a new biological medicine are complex and approval seems imminent after the second round of evaluation, we may request:
- a Certified Product Details (CPD) document
- pre-registration samples, standards and consumables for method development